$PAVM @10XXThanos (or anyone else that’s been here a while), can you confirm this run-up of almost 300% over the course of a month back in 2017 was the first attempt at CarpX Class II approval? If so, looking at where we are now, HOLY COW! PAVM has more products, has revenue, has a better pipeline, and has met all FDA in-human trials for CarpX. This may be a $10 stock faster than I originally estimated.
  • 9
  • 5